Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors

J Antimicrob Chemother. 2013 Feb;68(2):482-4. doi: 10.1093/jac/dks413. Epub 2012 Oct 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / pharmacokinetics*
  • Atazanavir Sulfate
  • Female
  • Humans
  • Male
  • Middle Aged
  • Oligopeptides / administration & dosage*
  • Plasma / chemistry
  • Pyridines / administration & dosage*
  • Pyrrolidinones / administration & dosage*
  • Pyrrolidinones / pharmacokinetics*
  • Raltegravir Potassium
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Ritonavir / administration & dosage*

Substances

  • Anti-HIV Agents
  • Oligopeptides
  • Pyridines
  • Pyrrolidinones
  • Reverse Transcriptase Inhibitors
  • Raltegravir Potassium
  • Atazanavir Sulfate
  • Ritonavir